AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29283132
Drug: Oral fenofibrate
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral fenofibrate 160 mg/day
Trial: 29283132
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment protocol (Control Group B)
Trial: 28814275
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose monotherapy (S-1 30 mg/m2 twice daily days 1-14 every 3 weeks, followed by second line irinotecan 250-350 mg/m2 iv day 1 every 3 weeks or 180-250 mg/m2 iv day 1 every 2 weeks)
Trial: 28814275
Drug: Reduced dose
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced dose combination therapy (S-1 20 mg/m2 days 1-14 + oxaliplatin 100 mg/m2 iv day 1 every 3 weeks, followed by second line S-1 20 mg/m2 days 1-14 + irinotecan 180 mg/m2 day 1 every 3 weeks)
Trial: 26316345
Drug: Apixaban 5
RxNorm normalized name: apixaban 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban 5 mg BID
Trial: 23292524
Drug: Atropine treatment
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine treatment for myopia
Trial: 8867520
Drug: terguride (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terguride (1 mg b.i.d.)
Trial: 8867520
Drug: levodopa (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levodopa (250 mg p.o.)
Trial: 1638712
Drug: Enalapril (2.5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (2.5-20 mg/day)
Trial: 15859528
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BTX‐A) treatment of the lower extremity
Trial: 12602111
Drug: Pulsed magnetic
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pulsed magnetic field therapy
Trial: 7582337
Drug: Wet-to-dry saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wet-to-dry saline gauze dressings changed twice a day
Trial: 1660009
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 10,000 anti Xa units of LMWH
Trial: 1660009
Drug: Aortic administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aortic administration before clamping of 10,000 anti Xa units of LMWH
Trial: 1660009
Drug: Intra-aortic administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-aortic administration of 10,000 anti Xa units of LMWH
Trial: 1660009
Drug: Aortic injection
RxNorm normalized name: chloroxylenol / hydrocortisone / pramoxine hydrochloride Otic Solution [Cortic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aortic injection after clamping of 10,000 anti Xa units of LMWH
Trial: 26778165
Drug: Early oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early oral β blockers (administered ≤24 hours after hospital admission)
Trial: 26778165
Drug: Delayed oral
RxNorm normalized name: lipase 12,000 UNT / amylase 39,000 UNT / protease 39,000 UNT Delayed Oral Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed oral β blockers (administered >24 hours after hospital admission)
Trial: 25484042
Drug: ch‐mAb7F9, doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ch‐mAb7F9, doses of 0.2 to 20 mg/kg
Trial: 18839190
Drug: Ultrasound-guided steroid
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided steroid injections
Trial: 18839190
Drug: Palpation-guided steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palpation-guided steroid injections
Trial: 18839190
Drug: Scintigraphy-guided steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scintigraphy-guided steroid injections
Trial: 18839190
Drug: Comparison among
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison among ultrasound-guided, palpation-guided, and scintigraphy-guided injections
Trial: 8276367
Drug: Glypressin (2-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glypressin (2-mg injection)
Trial: 2735328
Drug: sucralfate 2
RxNorm normalized name: sucralfate 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sucralfate 2 g at night
Trial: 2735328
Drug: cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cimetidine 400 mg
Trial: 1172718
Drug: Warfarin sodium
RxNorm normalized name: Warfarin Sodium
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Warfarin sodium added to chemotherapy
Trial: 31220851
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of TLD (29 W and 32 W)
Trial: 26055693
Drug: New reduced-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New reduced-dose Td vaccine
Trial: 26055693
Drug: Commercially available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available Td vaccine
Trial: 21114896
Drug: Cognitive Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Control (CC) task
Trial: 18289563
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg intravenous papaverine hydrochloride
Trial: 18289563
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg intramuscular sodium diclofenac
Trial: 16048734
Drug: Zolpidem (ZOL)
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zolpidem (ZOL) 10 mg orally
Trial: 16048734
Drug: Brotizolam (BTM)
RxNorm normalized name: brotizolam
DrugBank: Brotizolam (DB09017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brotizolam (BTM) 0.25 mg orally
Trial: 12480612
Drug: Tobramycin solution
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin solution for inhalation, 300 mg, twice daily for 28 days
Trial: 11190906
Drug: 325 mg
RxNorm normalized name: lysine 325 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 325 mg of aspirin every third day
Trial: 11190906
Drug: 81 mg
RxNorm normalized name: aspirin 81 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 81 mg of aspirin every day
Trial: 11190906
Drug: 81 mg
RxNorm normalized name: aspirin 81 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 81 mg of aspirin every third day
Trial: 11190906
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of aspirin every third day
Trial: 8422561
Drug: Chlormezanone 400
RxNorm normalized name: chlormezanone 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlormezanone 400 mg nocte
Trial: 25564105
Drug: Short-term medication-assisted
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term medication-assisted treatment (ST-MAT) with buprenorphine/naloxone (BUP/NX) for 1 year, including 2 opportunities for a 15-day detoxification and up to 21 sessions of behavioral drug and risk counseling
Trial: 25564105
Drug: Long-term medication-assisted
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term medication-assisted treatment (LT-MAT) with buprenorphine/naloxone (BUP/NX) for 48 weeks, including thrice-weekly dosing and up to 21 counseling sessions
Trial: 21112449
Drug: Behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral treatment program focused on weight loss
Trial: 21112449
Drug: Behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral treatment program focused on both weight loss and depression
Trial: 9310604
Drug: G‐CSF (filgrastim)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF (filgrastim) therapy
Trial: 3543342
Drug: Butoconazole vaginal
RxNorm normalized name: butoconazole Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butoconazole vaginal cream
Trial: 27413037
Drug: Heart failure
RxNorm normalized name: INVESTIGATIONAL CONGESTIVE HEART FAILURE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heart failure medication regimen (intense treatment)
Trial: 27413037
Drug: Higher blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher blood pressure and treatment with a β‐blocker or randomized to valsartan
Trial: 11515716
Drug: C-Med-100, 350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-Med-100, 350 mg x 2 daily for two months
Trial: 29614521
Drug: Dabigatran 110
RxNorm normalized name: dabigatran 110 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran 110 mg twice daily or intravenous argatroban
Trial: 29614521
Drug: Subcutaneous enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous enoxaparin 40 mg once daily
Trial: 24427665
Drug: Clonidine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (5 µg/Kg)
Trial: 10634816
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (10 mg/d for 2 weeks)
Trial: 1556522
Drug: Evening insulin
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening insulin therapy (Monotard HM or Ultratard HM), initial dose 10-16 U, mean dose 23 U d‐1 at 12 months
Trial: 1556522
Drug: Evening insulin
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening insulin therapy
Trial: 29545530
Drug: Morphine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine infusion as PCIA (morphine group)
Trial: 26810403
Drug: Ingenol mebutate
RxNorm normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ingenol mebutate (IngMeb) 0.015% daily for 3 days followed by clobetasol propionate (0.05%) twice daily for 4 days
Trial: 26810403
Drug: Ingenol mebutate
RxNorm normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ingenol mebutate (IngMeb) 0.015% daily for 3 days
Trial: 22270198
Drug: DCN and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCN and vehicle (initial treatment)
Trial: 17928105
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 mg/day) plus placebo
Trial: 17928105
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 mg/day) plus pindolol (7.5 mg/day)
Trial: 12776276
Drug: Intravenous vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vitamin C, 500 mg, three times a week
Trial: 6148617
Drug: Intravenous followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous followed by oral propranolol
Trial: 26977625
Drug: Venlafaxine (75-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine (75-150 mg/day for 4 weeks)
Trial: 26977625
Drug: Venlafaxine (75-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine (75-150 mg/day for 4 weeks) plus cerebrolysin (20 i/v infusions during 4 weeks, 20.0 ml in 100 ml isotonic NaCl solution)
Trial: 22432114
Drug: Fenofibrate therapy
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenofibrate therapy (case subjects, n = 321)
Trial: 12297844
Drug: 3 MU
RxNorm normalized name: Orasep Reformulated Dec 2013 Mucosal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 MU IFN alfa‐2b 3 times per week plus ribavirin 1,000 mg/d for 12 months (Group A)
Trial: 2552600
Drug: Nedocromil sodium,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium, 4 mg four times daily by inhalation
Trial: 1091305
Drug: Electrosleep (ES)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrosleep (ES) treatment; five half-hour sessions; duration not specified.
Trial: 21874260
Drug: BCAA (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA (12 g/day)
Trial: 31169723
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (C group) with 5 small round patches of adhesive pads positioned bilaterally at the same points.
Trial: 29275795
Drug: Classical acupuncture
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Classical acupuncture with placebo tablet
Trial: 29275795
Drug: Sham acupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham acupuncture with placebo tablet
Trial: 29275795
Drug: Sham acupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham acupuncture with ibuprofen
Trial: 21925346
Drug: pantethine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pantethine (600 mg/d for weeks 1-8, then 900 mg/d for weeks 9-16)
Trial: 12806269
Drug: Antidepressants (SSRIs)
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants (SSRIs)
Trial: 16773951
Drug: Antidepressants (non-specific)
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants (non-specific)
Trial: 12957419
Drug: Aspirin (325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (325 mg/day for four weeks)
Trial: 25855628
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg prednisone daily for 5 days
Trial: 25855628
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg prednisone daily for 14 days
Trial: 25855628
Drug: Prednisone treatment
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone treatment (both 5 and 14 days)
Trial: 18078906
Drug: Contrast material
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast material containing 300 mg iodine/mL (Iomeprol 300) injected at a rate of 1 g of iodine/second
Trial: 18078906
Drug: Contrast material
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast material containing 400 mg iodine/mL (Iomeprol 400) injected at a rate of 1 g of iodine/second
Trial: 16610157
Drug: Internet-based cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive-behavioral therapy (n = 26)
Trial: 12826971
Drug: Fentanyl (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (2 microg/kg intravenous)
Trial: 11596665
Drug: Perindopril-indapamide combination
RxNorm normalized name: indapamide / perindopril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril-indapamide combination (ACE inhibitor-diuretic)
Trial: 11596665
Drug: Usual guidelines-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual guidelines-based therapy for glucose control
Trial: 8285750
Drug: Milk feeds
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk feeds supplemented with Lactobacillus GG 10(8) colony forming units twice a day for two weeks
Trial: 3578848
Drug: 0.02% morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02% morphine
Trial: 3578848
Drug: Saline (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (30 ml perineurally and 1 ml intramuscularly) with 6 mg morphine
Trial: 30123060
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C and E supplementation (2000 mg/d vitamin C; 1400 U/d vitamin E)
Trial: 27062334
Drug: Guideline-concordant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-concordant therapy
Trial: 27062334
Drug: Empiric therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empiric therapy (sulbactam/ampicillin or ceftriaxone)
Trial: 25023798
Drug: Meloxicam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam (1 mg/kg of BW) administered orally at loading (d 0), unloading (d 1), and daily from d 2 to 7 of feedlot receiving (MEL)
Trial: 25023798
Drug: Lactose monohydrate
RxNorm normalized name: Lactose Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose monohydrate (1 mg/kg of BW) administered orally (TRANS)
Trial: 25023798
Drug: Lactose monohydrate
RxNorm normalized name: Lactose Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose monohydrate (1 mg/kg of BW) administered orally (CON)
Trial: 25023798
Drug: Meloxicam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam (1 mg/kg of BW) administered orally (MEL)
Trial: 23467862
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A injections prior to cast treatment
Trial: 23467862
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (cast treatment and botulinum toxin A)
Trial: 18572334
Drug: Alendronate 20
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate 20 mg once weekly
Trial: 12694145
Drug: Rectal paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal paracetamol 1000 mg four times daily
Trial: 12694145
Drug: Rectal paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal paracetamol 1000 mg
Trial: 12694145
Drug: Higher paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher paracetamol concentration
Trial: 10894579
Drug: Digital rectal
RxNorm normalized name: BD Thermometer Digital Rectal (obsolete)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital rectal examination (DRE) in patients with AMI (Group I)
Trial: 10894579
Drug: Digital rectal
RxNorm normalized name: BD Thermometer Digital Rectal (obsolete)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital rectal examination (DRE) in patients without AMI (Group III)
Trial: 3812055
Drug: Physician advice
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Physician advice plus nicotine chewing gum (NCG) prescription
Trial: 22170177
Drug: Magnesium infusion
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium infusion within 4 days (Group I)
Trial: 10732143
Drug: LH (Luteinizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LH (Luteinizing Hormone)
Trial: 10732143
Drug: FSH (Follicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FSH (Follicle Stimulating Hormone)
Trial: 7496933
Drug: Acetaminophen (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (1,000 mg every 6 h for 2 days)
Trial: 2683263
Drug: Cyclosporine (CsA)
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (CsA) 10 mg/kg/day and prednisone
Trial: 890617
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of prophylactic systemic antibiotics in high-risk patients
Trial: 31943807
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (NAPLS2)
Trial: 26895652
Drug: Dynamic light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic light application (DLA) therapy, administered through ceiling-mounted fluorescent tubes delivering bluish-white light up to 1700 lux between 0900 h and 1600 h, except for 1130-1330 h when dimmed to 300 lux.
Trial: 24388379
Drug: Ketotifen 0.025%
RxNorm normalized name: KETOTIFEN 0.025% OPH SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen 0.025% ophthalmic solution, one drop twice daily for 28 days
Trial: 24388379
Drug: Olopatadine 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olopatadine 0.1% ophthalmic solution, one drop twice daily for 28 days
Trial: 18376350
Drug: Incretin effect
RxNorm normalized name: Secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Incretin effect calculated using insulin responses
Trial: 15649722
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg acetylsalicylic acid (ASA)
Trial: 12165118
Drug: DITPA 1.875
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DITPA 1.875 mg/kg daily for 2 weeks, then 3.75 mg/kg daily for 2 weeks
Trial: 10442508
Drug: Ginger rhizome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger rhizome extract (2 x 100 mg)
Trial: 580623
Drug: Propylthiouracil, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propylthiouracil, 150 mg every eight hours
Trial: 580623
Drug: Propylthiouracil, 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propylthiouracil, 450 mg as a single daily dose
Trial: 580623
Drug: Switching to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching to propylthiouracil, 150 mg every eight hours after initial failure